Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual ...
Evercore ISI analyst Liisa Bayko maintained a Buy rating on Altimmune (ALT – Research Report) on February 28 and set a price target of $25.00.
Meriaura Group Plc's annual report including the annual accounts, the report of the Board of Directors and the auditor's report for the year 2024 has been published.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback